sellWeak cluster of 310b5-1 plan
Jane Henderson sold $113k of APGE
Chief Financial Officer at Apogee Therapeutics, Inc.. 1,500 shares at an average of $75.00, traded Dec 4, 2025, filed Dec 5, 2025.
Warning score
27Value
$113k
1,500 shares
Holdings after
194,871
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +10Trade size$112k at market
- 0Share of holdings soldSold 0.8% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-118985, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 4, 2025 | SOpen-market sale Common Stock10b5-1 | -1,500 | $75.00 | $113k | 194,871 | Dec 5, 2025 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $170k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.5M 20,000 shares | -2% | |
| 11Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $391k 5,500 shares | -3% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $140k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.3M 20,000 shares | -2% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $132k 2,000 shares | -1% | |
| 10Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $362k 5,500 shares | -3% | |
| 75Notable | Apogee Therapeutics, Inc. | Fairmount Funds Management LLC director | $134M 1,750,000 shares | -85% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.6M 20,000 shares | -2% | |
| 20Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $1.5M 18,700 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.